Begin main content

Call for Patient Input and Clinical Experts: Mayzent and brolucizumab

August 28, 2019
CADTH has received the following notice(s) of pending drug submission(s). Brand name Mayzent TBC Generic name siponimod brolucizumab Manufacturer Novartis Pharmaceuticals Canada Inc. Novartis Pharmaceuticals Canada Inc. Indication(s) For the treatment of patient with secondary progressive...

CADTH Pharmaceutical Reviews Update — Issue 10

August 22, 2019
See CADTH Pharmaceutical Reviews Update — Issue 10 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include: an extension of the feedback period on the ongoing consultations an updated procedure for implementation-phase clinical panels the upcoming announcement of a pilot p...

New at CADTH - August 2019

August 12, 2019
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.

Pharmaceutical Reviews Update — Issue 9

July 31, 2019
See Pharmaceutical Reviews Update – Issue 9 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include: the announcement of CADTH’s new Patient and Community Advisory Committee opportunities for stakeholder comments and feedback on proposed updates to CADTH’s pharmaceutic...